Crossmark

Do LORIS Trial Eligibility Criteria Identify a Ductal Carcinoma In Situ Patient Population at Low Risk of Upgrade to Invasive Carcinoma?

Published Online: 2016-05-12

Published Print: 2016-10

Authors

Pilewskie, Melissa

Stempel, Michelle

Rosenfeld, Hope

Eaton, Anne

Van Zee, Kimberly J. https://orcid.org/0000-0001-9550-4647
Morrow, Monica
Funding

Funding for this research was provided by:

NIH/NCI Cancer Center Support Grant (P30 CA008748)
License Information

Text and Data Mining valid from 2016-05-12

Document is current